U.S. President Donald Trump signed an executive order aimed at expanding access to in vitro fertilization (IVF) and reducing treatment costs. The order directs the administration to develop policy recommendations within 90 days to protect IVF access and lower expenses. However, it does not specify funding sources.
Currently, most states do not mandate insurance coverage for IVF, which involves fertilizing eggs and sperm in a lab. Even with insurance, costs can range from $12,000 to $25,000 per cycle, often requiring multiple attempts. The White House stated that over 85,000 babies were born through IVF in 2021, citing data from the Department of Health and Human Services.
Trump’s order seeks to remove unnecessary legal and regulatory hurdles that drive up costs, reinforcing his campaign promise to ensure government or insurance-backed IVF funding. The U.S. fertility rate has been declining, dropping 3% in 2023 and averaging a 2% annual decrease between 2014 and 2020. In 2022, the birth rate was 1.67 births per woman, below the 2.1 replacement rate necessary for population stability without immigration.
IVF became a key election issue following a controversial Alabama Supreme Court ruling that classified embryos as children, raising concerns about embryo storage and transportation. The decision led some patients to consider moving their embryos out of the state. Senate Republicans blocked Democratic-led IVF protection legislation twice in 2024, arguing that access was not at risk.
Trump’s executive order mandates a review of policies contributing to high IVF costs, including those requiring legislative changes. His initiative underscores the growing political focus on reproductive healthcare and its impact on families struggling with infertility.


Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure
Trump Appoints Colin McDonald as Assistant Attorney General for National Fraud Enforcement
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants
New York Legalizes Medical Aid in Dying for Terminally Ill Patients
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Trump Orders DHS to Avoid Protests in Democratic Cities Unless Federal Assets Are Threatened
Trump Administration Sued Over Suspension of Critical Hudson River Tunnel Funding
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Trump Administration Expands Global Gag Rule, Restricting U.S. Foreign Aid to Diversity and Gender Programs 



